Memac

Donepezil, the active ingredient in Memac, is an acetylcholinesterase inhibitor presented as a strength/form for oral use. It treats Alzheimer’s disease in adults by improving cognitive function and daily living activities. GNH USA supplies Memac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Donepezil is indicated for the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

Alzheimer’s disease (mild): Improves memory recall and attention in early‑stage patients. Alzheimer’s disease (moderate): Helps maintain daily functioning and slows functional decline. Alzheimer’s disease (all stages): Supports overall cognitive performance and may reduce caregiver burden.

Donepezil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Diarrhea - Insomnia - Muscle cramps - Fatigue - Loss of appetite

Serious or Rare Side Effects: - Bradycardia or heart block - Severe gastrointestinal bleeding - Seizures - Hepatic injury - Cardiac arrhythmias - Stevens‑Johnson syndrome or toxic epidermal necrolysis

When prescribing Donepezil, clinicians should consider several safety aspects. - Renal impairment: Assess renal function and adjust if necessary. - Hepatic impairment: Use with caution in patients with liver disease. - Cardiac disease: Monitor heart rate and rhythm, especially in patients with bradycardia. - Seizure history: Evaluate risk of seizure exacerbation. - Pregnancy: Safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: Keep in original container, protect from moisture and direct sunlight.

Donepezil can interact with several drug classes, requiring careful review.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) – may increase plasma levels. - Anticholinergic agents – opposite pharmacologic effect. - Concurrent use with other acetylcholinesterase inhibitors – risk of excessive cholinergic activity.

Moderate Interactions (Monitor Closely): - Beta‑blockers – may enhance bradycardia. - NSAIDs – increased risk of gastrointestinal bleeding. - Diuretics – potential electrolyte disturbances.